228581-79-1Relevant academic research and scientific papers
Synthesis of pyrazolopyrimidinones as sildenafil derivatives and sclerotigenin
Heo, Hoon Gu,Yu, Jin,Jillella, Raveendra,Oh, Chang Ho
, p. 1678 - 1687 (2018/06/14)
A series of novel pyrazolo pyrimidinone derivatives (3(a–d), 4(a–d), and 6(a–d)) was synthesized from various pyrazolo amides (2a–d) which are synthesized by the reaction between ethyl 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (1) and various lithium amides. In addition, we also described the synthesis of sclerotigenin drug molecule which has quinazoline moiety from simple 2-nitro benzoic acid with high yields.
ANTIVIRAL COMPOUNDS
-
Paragraph 0246; 0247; 0248, (2013/08/28)
The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
Synthesis, biological evaluation, and structure-activity relationships of 2-[2-(benzoylamino)benzoylamino]benzoic acid analogues as inhibitors of adenovirus replication
?berg, Christopher T.,Strand, M?rten,Andersson, Emma K.,Edlund, Karin,Tran, Nam Phuong Nguyen,Mei, Ya-Fang,Wadell, G?ran,Elofsson, Mikael
experimental part, p. 3170 - 3181 (2012/06/04)
2-[2-Benzoylamino)benzoylamino]benzoic acid (1) was previously identified as a potent and nontoxic antiadenoviral compound (Antimicrob. Agents Chemother. 2010, 54, 3871). Here, the potency of 1 was improved over three generations of compounds. We found that the ortho, ortho substituent pattern and the presence of the carboxylic acid of 1 are favorable for this class of compounds and that the direction of the amide bonds (as in 1) is obligatory. Some variability in the N-terminal moiety was tolerated, but benzamides appear to be preferred. The substituents on the middle and C-terminal rings were varied, resulting in two potent inhibitors, 35g and 35j, with EC50 = 0.6 μM and low cell toxicity.
NEW ANTIVIRAL COMPOUNDS
-
Page/Page column 36-37, (2012/01/05)
The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
